GlassScriptPhysician profile
Daniel Reinharth
NPI 1801875059
$1,690.16
in general payments reported to CMS, 2019-2025
20 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $57.93 · 2021: $423 · 2022: $413 · 2023: $421 · 2024: $100 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $378.86 | 2021-2024 | Wegovy |
| Abbvie INC. | $317.40 | 2021-2025 | |
| Glaxosmithkline, LLC. | $159.67 | 2020-2023 | Trelegy Ellipta, Bexsero, Shingrix |
| Amgen INC. | $141.78 | 2020-2025 | Evenity, Prolia, Krystexxa |
| Abbott Laboratories | $105.53 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $81.76 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $79.58 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $79.43 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $71.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $48.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.92 | 2019-2021 | |
| Lilly USA, LLC | $30.76 | 2021 | |
| Mylan Specialty L.P. | $26.03 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $24.61 | 2022 | |
| Exact Sciences Corporation | $20.98 | 2023 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $19.05 | 2022 | |
| Inspire Medical Systems, INC. | $18.04 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $16.81 | 2022 | |
| Janssen Biotech, INC. | $16.53 | 2024 | Stelara |
| E.R. Squibb & Sons, L.L.C. | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Reinharth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.